.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
AstraZeneca
Citi
Julphar
Federal Trade Commission
Cerilliant
Fish and Richardson
Boehringer Ingelheim
McKesson
UBS

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202219

« Back to Dashboard
NDA 202219 describes LITHIUM CARBONATE, which is a drug marketed by Hetero Labs Ltd Iii, Watson Labs, West-ward Pharms Int, Hikma Intl Pharms, Glenmark Generics, Mylan Pharms Inc, Able, Sun Pharm Inds Inc, Heritage Pharma, Pfizer, Usl Pharma, Glenmark Pharms Inc, Alembic Pharms Ltd, Alembic Ltd, Unique Pharm Labs, Barr, and Apotex Inc, and is included in twenty-nine NDAs. It is available from thirty-three suppliers. Additional details are available on the LITHIUM CARBONATE profile page.

The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.

Summary for 202219

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202219

Medical Subject Heading (MeSH) Categories for 202219

Suppliers and Packaging for NDA: 202219

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LITHIUM CARBONATE
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL 202219 ANDA Mylan Pharmaceuticals Inc. 0378-1450 0378-1450-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-1450-01)
LITHIUM CARBONATE
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL 202219 ANDA Mylan Institutional Inc. 51079-142 51079-142-20 100 BLISTER PACK in 1 CARTON (51079-142-20) > 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (51079-142-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength450MG
Approval Date:Aug 8, 2012TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Novartis
Boehringer Ingelheim
US Department of Justice
US Army
Deloitte
Accenture
Baxter
Cerilliant
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot